Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The novel transcript antisense to COL23A1 (ENSG00000307780) is an annotated genomic element located opposite the COL23A1 gene, which encodes Collagen type XXIII alpha 1 chain, a transmembrane collagen associated with tissue structure and implicated in cancer progression. The antisense transcript's function is unknown; it may regulate its neighboring gene post-transcriptionally, but no formal disease association, drug targeting, or clinical biomarker role has been described. It is not a classic "target" in the sense of common druggable receptors, enzymes, or transporters.
None described for drugs, as there are no known drugs targeting either the antisense transcript or COL23A1 protein directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to COL23A1.